Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $5.00 Analyst target: $53.50 Upside: 970.00%
Palatin Technologies, Inc., a specialty biopharmaceutical company, develops targeted receptor-specific therapies for the treatment of various diseases in the United States. The company is headquartered in Cranbury, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.